Quest Diagnostics Hits New 52-Week High at $240.00, Up 66.85%

Quest Diagnostics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 240.00 on August 13, 2026. This achievement underscores the company's strong performance in the market, particularly as it has demonstrated a remarkable 66.85% increase over the past year, significantly outpacing the S&P 500's 20.6% gain during the same period. With a market capitalization of USD 31,451 million, Quest Diagnostics operates within the miscellaneous industry and is classified as a mid-cap company. The stock's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation in relation to earnings. Additionally, the company boasts a robust dividend yield of 29.40%, indicating a commitment to returning value to shareholders. Financial metrics reveal a strong operational foundation, with a return on equity of 15.54% and a debt-to-equity ratio of 0.75, suggesting effective management of financial obligations. The company's operating cash flow reached a record high of USD 1,678 million, while net sales for the quarter peaked at USD 2,761 million. These indicators highlight Quest Diagnostics' solid market position and operational efficiency as it continues to navigate the competitive landscape.